RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.
Cella, D., Hackshaw, M. D., Vondeling, G. T., Bennett, L., Garbinsky, D., Saito, K., Sugihara, M., Bang, Y., Yamaguchi, K., & Shitara, K. (2021). Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.Journal of Clinical Oncology, 39(15), 4057. https://doi.org/10.1200/jco.2021.39.15_suppl.4057